Search research articles
Contact Us
Filters
Showing results (31-40 of 418) with videos related to
Page
of 42
Sort By:
Expert Opinion on Investigational Drugs
|
April 22, 2011
New targeted therapies for renal cell carcinoma
Rosalie Fisher, Lisa Pickering, James Larkin
Future Oncology (London, England)
|
June 1, 2012
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation
Kate Young, Anna Minchom, James Larkin
Cell
|
December 7, 2015
SnapShot: Renal Cell Carcinoma
Samra Turajlic, James Larkin, Charles Swanton
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 16, 2020
Checkpoint Inhibitor-associated Cutaneous Small Vessel Vasculitis: A Review of the Literature
Bernard Ho, James Larkin, Kara Heelan
Health Promotion International
|
December 10, 2024
Commercial influences on patient and public involvement: a renewed call for research and action
Marita Hennessy, Tom Fahey, James Larkin
Expert Opinion on Biological Therapy
|
February 3, 2025
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges
Sowmya Cheruvu, David McMahon, James Larkin
Cell
|
December 23, 2022
Relatlimab and nivolumab in the treatment of melanoma
Lewis Au, James Larkin, Samra Turajlic
Melanoma Management
|
September 8, 2018
High-risk cutaneous melanoma follow-up: time for more intensive surveillance?
Michael Davidson, Paul Lorigan, James Larkin
International Dental Journal
|
March 20, 2026
Corrigendum to 'Prompt-Driven ChatGPT Carbon Calculator for Dental Practices: Estimation and Tailored Improvement Strategies' [Volume 76, Issue 1, February 2026, 103979]
Brett Duane, Paul Ashley, James Larkin
Therapeutic Advances in Urology
|
October 2, 2012
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
Manuela Schmidinger, James Larkin, Alain Ravaud
Page
of 42
Search research articles
Search
Showing results (31-40 of 418) with videos related to
Sort By:
Page
of 42
Expert Opinion on Investigational Drugs
|
April 22, 2011
New targeted therapies for renal cell carcinoma
Rosalie Fisher, Lisa Pickering, James Larkin
Future Oncology (London, England)
|
June 1, 2012
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation
Kate Young, Anna Minchom, James Larkin
Cell
|
December 7, 2015
SnapShot: Renal Cell Carcinoma
Samra Turajlic, James Larkin, Charles Swanton
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 16, 2020
Checkpoint Inhibitor-associated Cutaneous Small Vessel Vasculitis: A Review of the Literature
Bernard Ho, James Larkin, Kara Heelan
Health Promotion International
|
December 10, 2024
Commercial influences on patient and public involvement: a renewed call for research and action
Marita Hennessy, Tom Fahey, James Larkin
Expert Opinion on Biological Therapy
|
February 3, 2025
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges
Sowmya Cheruvu, David McMahon, James Larkin
Cell
|
December 23, 2022
Relatlimab and nivolumab in the treatment of melanoma
Lewis Au, James Larkin, Samra Turajlic
Melanoma Management
|
September 8, 2018
High-risk cutaneous melanoma follow-up: time for more intensive surveillance?
Michael Davidson, Paul Lorigan, James Larkin
International Dental Journal
|
March 20, 2026
Corrigendum to 'Prompt-Driven ChatGPT Carbon Calculator for Dental Practices: Estimation and Tailored Improvement Strategies' [Volume 76, Issue 1, February 2026, 103979]
Brett Duane, Paul Ashley, James Larkin
Therapeutic Advances in Urology
|
October 2, 2012
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
Manuela Schmidinger, James Larkin, Alain Ravaud
Page
of 42